Genentech turns eye implant's focus to diabetes
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME),
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...
Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...
(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a WARN notice from the California Employment Development Department (EDD).
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles ...
Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...
Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...
A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...
Joshua Nair is a driven Principal Administrative Business Partner and Operations Manager at Genentech, with over a decade of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback